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The causes of antibiotic resistance are often complex and it is difficult to identify strategies to prevent
or delay its emergence. One strategy has been to use less active members of a drug class, so that
when resistance develops the more active members will still prevail. This stratagem may often fail
because this resistance may form the basis of resistance to the whole class. Often, less active drugs
are the first to be discovered and more active versions follow, so we have had no choice; however,
increasingly less active drugs are available to deal with specific infections and this may have a detri-
mental effect on the class as a whole.
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In the 1990s, the WHO recommended the use of the quinolone
nalidixic acid for the treatment of infections caused by Shigella
spp. in southern Asia; however, nalidixic acid has relatively low
activity. Its use has been shown to select a mutation in codon 83
of the gyrA gene,1 giving high-level resistance. However, this is
also the first mutation required for resistance to the much more
active fluoroquinolone, ciprofloxacin.1 Therefore the use of this
drug appears implicated in the preliminary stage on the pro-
gression to ciprofloxacin resistance. The WHO rationale was that
the use of the less active compound would preserve the more
active drugs when resistance developed. The tactic appears
flawed as nalidixic acid resistance and a concomitant decrease
in ciprofloxacin susceptibility emerged in Shigella spp. at
the end of the 20th century compromising future use of the
fluoroquinolones.2
The stratagem of using less active drugs first has long been
part of microbiology folklore. However, it ignores the fact that
resistance to one member of a drug class often brings resistance
to the whole class and that less active class members are often
more adept at selecting resistance than their more active counter-
parts. The use of the earlier, poorly penetrating fluoroquino-
lones, such as pefloxacin in France, for the treatment of
infections caused by Acinetobacter baumannii has been associ-
ated with rapid increases in resistance not only to pefloxacin but
also to ciprofloxacin.3,4 The same principle could be seen with
the introduction of the anti-Gram-positive fluoroquinolones for
the treatment of Streptococcus pneumoniae. These drugs were
being compromised by the concurrent usage of fluoroquinolones
that were designed primarily for anti-Gram-negative use but
were less effective against Gram-positive bacteria.5,6
The use of less active drugs has also been associated with the
emergence of the TEM-derived extended-spectrum b-lactamases
(ESBLs). Cefotaxime is a fast penetrating cephalosporin in
Enterobacteriaceae, whereas ceftazidime penetrates more slowly.
However, ceftazidime was used extensively against Klebsiella
infections and the initial ESBL mutations arose rapidly. Once
formed, the subsequent mutations that broadened the spectrum
of ESBL activity could be selected more readily.7 The impact of
the ESBLs is now well known and has largely stopped all cepha-
losporin development for Gram-negative infections. The last
major cephalosporins to be launched against Gram-negative
bacilli were cefepime and cefpirome, which are fast penetrating
cephalosporins in the Enterobacteriaceae. Had these drugs been
used at the beginning, then it is likely that the development of
resistance would have, at least, been delayed. Instead, the use of
poorer-penetrating cephalosporins selected resistance that even
the superior qualities of cefepime and cefpirome may not be
able to overcome.8
The major drug class of last resort for Gram-negative bacteria
is the carbapenems. Imipenem and meropenem are very active
against most Gram-negative bacteria, though there are
b-lactamases (carbapenemases) capable of conferring resistance.
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However, resistance has been quite slow to develop and is vir-
tually non-existent in some species. This has encouraged the
development of less active carbapenems, such as ertapenem,
aimed mainly at Enterobacteriaceae causing community-acquired
infections. However, its usage has been advocated more widely,9
but only in areas where there is no risk of infection by non-
fermenters, which is difficult to guarantee in hospitals. As erta-
penem is believed to have no activity against non-fermenting
organisms, such as Pseudomonas aeruginosa and A. baumannii,
its use would not preferentially select variants of these bacteria
resistant to the more active carbapenems. It has been suggested
that this concept is flawed and likely to select resistance in non-
fermenting pathogens.10 This can be demonstrated in vitro if a
mixture of two A. baumannii strains, one harbouring the carba-
penemase OXA-65 and the other lacking it, are challenged with
ertapenem in the ratio of 1:99. In the absence of antibiotics, the
ratio of the strains remains constant with the carbapenemase-
negative strain dominating the culture. However, on challenge
with ertapenem, the carbapenemase-containing strain soon takes
over the population; so this carbapenem is selecting a carbape-
nemase that encodes resistance to all carbapenems (personal
observation).
With increasing knowledge of pharmacodynamics and the
molecular mechanisms of antibiotic resistance, antibiotic
dosages can be more intelligently selected based on the desired
antibiotic exposure at the site of infection. The use of more
active bactericidal agents that provide increased free drug
activity (without increased toxicity) is likely to provide a lethal
antibiotic exposure to the pathogen. In many instances, we now
have knowledge of the drug exposure required to kill organisms
that may already have developed single-step mutations, leading
to only modest increases in the organism’s MIC. If a less active
antibiotic is used, selection of the single-step mutants is facili-
tated, which then allows for the development of further
mutations, thereby rendering the pathogen resistant to all agents
in the class. Development of resistant pathogens impacts both
the patient and other patients in the hospital unit. Antibiotic-
resistant pathogens are more likely to cause subsequent infec-
tions in that patient, as well as spread to other patients if
infection control techniques are not stringently followed.
Prevention of the development of resistant organisms by using
the appropriate antibiotic at the appropriate dosage not only pro-
tects the patients in the institution, but it prolongs the useful life
of the class of agents and prevents the need for the use of other,
potentially more toxic agents. Using more active agents in one
class of antibiotics may decrease the need for novel agents
targeting multidrug-resistant organisms.11
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